Stramsen Biotech Joins Elite Class of Unicorns at $6.5 Billion Valuation and a Potential Reverse Merger Deal

Stramsen is negotiating a potential acquisition and/or a reverse merger with several US-based publicly traded companies. HOUSTON, April 18, 2024 /PRNewswire/ — More than three years after establishment, Stramsen Biotech, Inc, is one of the leading plant-based biotech start-up companies…